57260-68-1

Basic information

• Product Name: 2-(1-PIPERAZINO)-BENZIMIDAZOLE
• Synonyms: 2-PIPERAZIN-1-YL-1H-BENZOIMIDAZOLE;2-(1-PIPERAZINO)-BENZIMIDAZOLE;2-Piperazin-1-yl-1H-benzimidazole dihydrochloride;2-(PIPERAZIN-1-YL)-1H-BENZO[D]IMIDAZOLE
• CAS NO: 57260-68-1
• Molecular Formula: C₁₁H₁₄N₄
• Molecular Weight: 202.26
• EINECS: 604-604-1
• Mol File: 57260-68-1.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 409°C at 760 mmHg
• Flash Point: 201.1°C
• Appearance: /
• Density: 1.237g/cm³
• Vapor Pressure: 6.72E-07mmHg at 25°C
• Refractive Index: 1.657
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2-(1-PIPERAZINO)-BENZIMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-PIPERAZINO)-BENZIMIDAZOLE(57260-68-1)
• EPA Substance Registry System: 2-(1-PIPERAZINO)-BENZIMIDAZOLE(57260-68-1)

Safety Data

• Hazardous Substances Data: 57260-68-1(Hazardous Substances Data)

Usage

General Description

2-(1-piperazino)-benzimidazole is a chemical compound with a molecular formula C11H13N3. It is a benzimidazole derivative that contains a piperazine moiety. 2-(1-PIPERAZINO)-BENZIMIDAZOLE has been studied for its potential pharmaceutical properties, including its antihistaminic and antipsychotic effects. It has also been investigated for its potential use as an anti-inflammatory and anti-cancer agent. Its structural features make it a promising candidate for further research and development in the field of medicinal chemistry.

InChI:InChI=1/C11H14N4/c1-2-4-10-9(3-1)13-11(14-10)15-7-5-12-6-8-15/h1-4,12H,5-8H2,(H,13,14)

Upstream product

• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 95-54-5 1,2-diamino-benzene 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 7542-23-6 piperazine hydrochloride 
• 110-85-0 piperazine 
• 142-64-3 piperazine dihydrochloride 
• 295341-56-9 tert-butyl 4-(1H-benzimidazol-2-yl)piperazine-1-carboxylate 
• 749878-99-7 ethyl 4-(1H-benzimidazol-2-yl)-piperazin-1-carboxylate 

Downstream Products

• 1061517-13-2 C₂₉H₂₈N₆O₂ 
• 1209218-74-5 2-[4-(p-tolylsulfonyl)piperazin-1-yl]-1H-benzimidazole 
• 1454676-43-7 [4-(1H-benzimidazol-2-yl)piperazin-1-yl]-(p-tolyl)methanone 
• 1159096-83-9 C₂₄H₂₂N₄O 
• 295790-30-6 N-(2-(4-(1H-benzimidazol-2-yl)piperazin-1-yl)ethyl)-2,4,5-trichloro-N-methyl-benzenesulfonamide 

Relevant articles and documents

Design, synthesis, characterization and evaluation of 1,3,5-triazine-benzimidazole hybrids as multifunctional acetylcholinesterases inhibitors

A series of hybrids of benzimidazole and 1,3,5-triazine were designed and synthesized and evaluated as multi-target agents for the treatment of Alzheimer's disease. 24 compounds were designed, synthesized and identified by NMR, IR, HRMS and single-crystal X-ray diffraction studies. The compound 6c had the crystal system of orthorhombic and the space group of P212121. The cholinesterase inhibitory activity of synthesized compounds was measured using colorimetric Ellman's method. Most 1,3,5-triazine-benzimidazole hybrids showed potent acetylcholinesterase-inhibition activities and weak butyrylcholinesterase inhibitory activities. Compound 9f possessed the best acetylcholinesterase inhibitory activity with the IC50 of 0.044 μM, which is better than donepezil (0.052 μM). Molecular docking and molecular dynamics simulations demonstrated that there is a stable interaction between compound 9f and acetylcholinesterase. Simultaneously, experiments have also proved that compound 9f has good metal chelating properties. ADMET in silico prediction results suggest the compound can pass through the blood-brain barrier well and have good drug similarity. So, compound 9f could be a multi-target agent for the treatment of Alzheimer's disease.

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis

Human African trypanosomiasis is a neglected tropical disease that is lethal if left untreated. Existing therapeutics have limited efficacy and severe associated toxicities. 2-(2-(((3-((1H-Benzo[d]imidazol-2-yl)amino)propyl)amino)methyl)-4,6-dichloro-1H-indol-1-yl)ethan-1-ol (NEU-1053) has recently been identified from a high-throughput screen of >42,000 compounds as a highly potent and fast-acting trypanocidal agent capable of curing a bloodstream infection of Trypanosoma brucei in mice. We have designed a library of analogues to probe the structure-activity relationship and improve the predicted central nervous system (CNS) exposure of NEU-1053. We report the activity of these inhibitors of T. brucei, the efficacy of NEU-1053 in a murine CNS model of infection, and identification of the target of NEU-1053 via X-ray crystallography.